Clinical Trial Update: Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients [Phase 2]

View source ↗

Summary

Phase 2 study evaluating post-transplant maintenance therapy with isatuximab plus lenalidomide for high-risk multiple myeloma; currently recruiting at MD Anders…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Revlimid (lenalidomide)
• SARCLISA (isatuximab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Multiple Myeloma | Phase 2 | Status: RECRUITING